Volume 10, Issue 2 , Pages 103-109, April 2009
Comparison of percutaneous coronary intervention in native coronary arteries vs. bypass grafts in patients with prior coronary artery bypass graft surgery☆☆☆
Abstract
Objective
To compare the procedural and clinical outcomes of prior coronary artery bypass graft surgery (CABG) patients undergoing percutaneous coronary intervention (PCI) in native arteries vs. bypass grafts.
Methods
The medical and catheterization records and the angiograms of 142 consecutive prior CABG patients who underwent 165 PCI of 247 lesions at our institution between January 1, 2003, and December 31, 2006, were retrospectively reviewed.
Results
Mean age was 66±10 years and 99% were men: 79 and 63 patients underwent native coronary or bypass graft PCI, respectively. Compared to patients undergoing bypass graft PCI, those undergoing native coronary artery PCI were younger (mean age 64±10 vs. 68±10 years, P=.008), more likely to present with stable angina (29% vs. 8%, P=<.001), and presented earlier after CABG (after a mean of 9±6 vs. 12±5 years, P<.01). Compared to bypass graft PCI, native coronary PCI was more likely to be performed with drug-eluting stents (88% vs. 57%, P<.001) and was associated with lower risk of no-reflow (3% vs. 24%, P<.001). After a mean follow-up of 2.5±1.1 years, both groups of patients had similar but high incidence of myocardial infarction, repeat PCI, and death.
Conclusions
Prior CABG patients undergoing native coronary artery PCI have lower procedural risk, but similar postprocedural clinical outcomes compared to patients undergoing bypass graft PCI. If feasible, native coronary arteries may be the preferred PCI target in prior CABG patients.
Abbreviations: CABG, coronary artery bypass graft surgery, CAD, coronary artery disease, MI, myocardial infarction, PCI, percutaneous coronary intervention, SVG, saphenous vein graft, TIMI, Thrombolysis In Myocardial Infarction.
Keywords: Coronary artery bypass graft surgery, Percutaneous coronary intervention, Stents
To access this article, please choose from the options below
☆ Emmanouil S. Brilakis is supported by the Clark R. Gregg Fund, Harris Methodist Health Foundation, 6100 Western Place, Suite 1001, Fort Worth, TX 76107, USA, and by a Veterans Affairs VISN 17 startup award, Waco, TX, USA.
☆☆ Conflict of interest: Subhash Banerjee has received speaker hononaria from St Jude, Medtronic, and Johnson and Johnson, and a research grant from Boston Scientific. Emmanouil Brilakis has received speaker honoraria from St Jude.
PII: S1553-8389(08)00299-6
doi:10.1016/j.carrev.2008.12.002
Published by Elsevier Inc.
Volume 10, Issue 2 , Pages 103-109, April 2009
